PedAM
Pediatric Disease Annotations & Medicines
| Disease | myocardial infarction |
| Phenotype | C0027051|heart attack |
| Sentences | 5 |
| PubMedID- 25465416 | Methods: tra 2 degrees p-timi 50 (trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50) was a multinational, randomized, double-blind, placebo-controlled trial of vorapaxar in stable patients with prior myocardial infarction, peripheral arterial disease, or stroke. |
| PubMedID- 26346960 | The trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (tra 2 degrees p-timi 50) investigated atherothrombotic events in patients with stable atherosclerosis. |
| PubMedID- 25813797 | This article reviews this new class of antiplatelet therapy in detail with an acute focus on the tracer (thrombin receptor antagonist for clinical event reduction in acute coronary syndrome) and tra 2 degrees p-timi 50 (trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50) trials. |
| PubMedID- 24926716 | Background: as an example of the process that could be used to evaluate and optimize the performance of quality measures in routine practice, we evaluated whether the healthcare effectiveness data and information set (hedis) measure assessing the "persistence of beta-blocker treatment after a heart attack" correlates with post-myocardial infarction (mi) outcomes and whether or not there are alternative specifications of this construct which are better predictors and/or may be more easily applied. |
| PubMedID- 25465417 | Methods: the tra 2 degrees p-timi 50 (trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar 2.5 mg daily in 26,449 patients with atherosclerosis, stratified by qualifying disease (mi, pad, or cvd). |
Page: 1